Stock Ratings / Health Care / PACB / options

CTKB (41) NAUT (41) ALMR (48) LAB (41) ⌘ Pro Terminal →

Pacific Biosciences of California Inc. (PACB) Options Positioning, Max Pain & Unusual Sweeps

$2.90 +2.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.91

Pacific Biosciences of California Inc. (PACB) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $901.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.91 (+0.25%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-9.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PACB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY PACB SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 28.6% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.33-25.8% Next Q

Q2 (-2Q)

Grade E$1.73+22% Next Q

Q3 (-1Q)

Grade E$2.11+37.4% Next Q

Current

Grade D-$2.90-8.1% Hist 90D α

Trajectory: E (29) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PACB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PACB currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.83) and Max Pain ($3.05) forces dealer call-delta covering toward $3.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PACB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PACB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PACB)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PACB.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PACB)

✓Walkthrough of PACB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PACB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +82.39%📐 HORIZONTAL RANGE

2026-10-30O $2.75H $2.90L $2.41C $2.90VOL 13.73M

RES: $3.79SUP: $1.05SMA50: $1.83SMA200: $1.61

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PACB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PACB Butterfly Map → + Track PACB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PACB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PACB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PACB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PACB)

Health Care Rank #742 of 1016 ⚔️ CTKB vs PACB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PACB vs. CTKB, NAUT, ALMR, LAB)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pacific Biosciences of California Inc. (PACB) ranks #742 by composite RQD confidence (37/100, grade D-) and #376 by equity capitalization ($901.4M). Within this direct 5-issuer industry benchmark cohort, PACB leads on earnings valuation at N/A trailing P/E, while CTKB leads on capital efficiency and profitability with -12.7% ROIC and 51.8% gross margin. ALMR currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with PACB at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PACB ACTIVE Pacific Biosciences of California Inc.	D-	37/100	—	28.6%	-35.0%	+2.47%	$901.4M	Benchmark Subject
CTKB Cytek Biosciences Inc.	D-	41/100	—	51.8%	-12.7%	+2.61%	$818.9M	/ctkb-vs-pacb →
NAUT Nautilus Biotechnology Inc.	D-	41/100	—	—	-35.0%	-2.18%	$399.9M	/naut-vs-pacb →
ALMR Alamar Biosciences Inc.	D	48/100	—	—	—	-0.76%	$2.36B	/almr-vs-pacb →
LAB Standard BioTools Inc.	D-	41/100	—	49.9%	-28.7%	+0.49%	$244.7M	/lab-vs-pacb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001299130

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pacific Biosciences of California Inc. (PACB) reported GAAP revenue of $160.0M (+3.9% vs. FY2024 revenue of $154.0M ) , GAAP net income of -$546.4M, operating cash flow of -$111.2M, and free cash flow of -$113.9M (+46.3% YoY). On the balance sheet, PACB closed FY2025 with $784.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$160.0M	-$546.4M	-$111.2M	-$113.9M	$784.1M	—
FY2024 (FY)	2024-12-31	$154.0M	-$309.9M	-$206.1M	-$212.2M	$1.26B	—
FY2023 (FY)	2023-12-31	$0	-$306.7M	-$259.2M	-$259.2M	—	—

3. PACB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PACB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Pacific Biosciences of California Inc. (NASDAQ: PACB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.90 (+2.47% 1D, market cap $901.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PACB ranks #742 in composite RQD confidence.

How does PACB compare to CTKB and NAUT in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), PACB carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 28.6%, and ROIC of -35.0%. By comparison, CTKB (Cytek Biosciences Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -12.7%, cap $818.9M) and NAUT (Nautilus Biotechnology Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $399.9M). Among the 5-stock peer group, PACB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PACB?

Per PACB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001299130), Pacific Biosciences of California Inc. generated $160.0M in revenue (+3.9% YoY), -$546.4M in net income, and -$113.9M in free cash flow against $784.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PACB trading relative to its 50-day, 200-day, and 52-week technical levels?

PACB last traded at $2.90 (+2.47% on volume of 11,974,007 shares), positioning the stock +58.47% above its 50-day simple moving average ($1.83) and +80.12% above its 200-day simple moving average ($1.61). Across its 52-week range of $1.07 to $3.44, PACB sits at the 77.2% percentile with a 14-day RSI of 61.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.54 to $3.26).

PACB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is PACB's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for PACB.

Direct Sub-Reports: PACB RQD Cockpit PACB 12M Forecast PACB Earnings & Move PACB Dividends & DRIP PACB Insiders & 13F PACB Whale Options PACB Profit Sankey PACB News & Why